For the quarter ending 2025-09-30, XBIO made $1,026,957 in revenue. -$509,940 in net income. Net profit margin of -49.66%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 1,026,957 | 589,897 | 593,261 | 614,243 |
| Research and development | 756,482 | 656,557 | 879,029 | 367,985 |
| General and administrative | 815,209 | 657,752 | 656,641 | 745,731 |
| Total operating costs and expenses | 1,571,691 | 1,314,309 | 1,535,670 | 1,113,716 |
| Loss from operations | -544,734 | -724,412 | -942,409 | -499,473 |
| Other income | 4,011 | 1,477 | 78 | 1,504 |
| Interest income, net | 30,783 | 34,232 | 39,190 | 61,298 |
| Total other income | 34,794 | 35,709 | 39,268 | 62,802 |
| Net loss | -509,940 | -688,703 | -903,141 | -436,671 |
| Basic net loss per share | -0.33 | -0.45 | -0.59 | -0.28 |
| Diluted net loss per share | -0.33 | -0.45 | -0.59 | -0.28 |
| Weighted-average shares of common stock outstanding, basic | 1,542,139 | 1,542,139 | 1,542,139 | 1,541,722 |
| Weighted-average shares of common stock outstanding, diluted | 1,542,139 | 1,542,139 | 1,542,139 | 1,541,722 |
Xenetic Biosciences, Inc. (XBIO)
Xenetic Biosciences, Inc. (XBIO)